This is an international, multicenter trial to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC. The active pharmaceutical ingredient is apraglutide, an investigational GLP-2 analogue. The trial consists of an evaluation period of 52 weeks.
The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.